Key result
Cystatin C assessment independently predicted elevated left ventricular filling pressure (E/E' > 15) at 6 months in patients with a first STEMI.
Why the study?
Does the addition of cystatin C to standard biomarkers improve the prediction of postinfarct LV dysfunction progression in patients with a first STEMI?
Cohort (n=150)
Does the addition of cystatin C to standard biomarkers improve the prediction of postinfarct LV dysfunction progression in patients with a first STEMI?
Multiple biomarkers, including cystatin C, can help predict the progression of left ventricular dysfunction and elevated filling pressures after a first STEMI.
Answers are grounded in this paper and cite their sources.
CystC may enhance post-MI LV dysfunction prediction; leaves open incremental value beyond NT-proBNP and CRP in risk models.
OBJECTIVES: Left ventricular (LV) dysfunction is a major cause of poor outcome after myocardial infarction. We sought to investigate the factors that might contribute to the prediction of postinfarct LV dysfunction progression, and whether the addition of cystatin C (CystC) to this assessment might be useful. METHODS: NT-proBNP, CRP, CystC, and troponin I were measured in 150 patients with a first ST-elevation myocardial infarction (STEMI) who were followed up for 6 months. Echocardiography was performed at discharge and follow-up. RESULTS: In multivariable logistic regression, LV ejection fraction decrease at follow-up exceeding 0.2 was independently predicted by CRP [odds ratio (OR): 1.09, 95% confidence interval (CI): 1.05-1.13, P<0.0001], multivessel disease (OR: 8.83, 95% CI: 4.01-19.41, P<0.001), and left anterior descending artery involvement (OR: 5.09, 95% CI: 1.60-16.22, P<0.006); whereas peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity ratio (E/E') exceeding 15 indicating elevated LV filling pressure by CystC (OR: 3.53, 95% CI: 1.11-11.26, P<0.01), diabetes (OR: 4.04, 95% CI: 1.58-10.58, P<0.005), and multivessel disease (OR: 4.09, 95% CI: 1.52-11.05, P<0.006). CRP, NT-proBNP, and CystC were among the independent determinants of clinical outcomes (heart failure hospitalizations, mortality, and recurrent ischemic events). Receiver operator characteristic analyses identified CRP being the most valuable in discriminating LV ejection fraction decrease exceeding 0.2 and CystC in discriminating E/E' exceeding 15. CONCLUSION: Using multiple biomarkers may contribute to the better prediction of LV dysfunction progression and the risk of adverse cardiac events in patients with STEMI. CystC may improve this evaluation, especially with regard to the development of echocardiographic features of elevated LV filling pressure.
No takes yet. Share an insight, caveat, or question.
Derzhko et al. (2009) conducted a cohort in First ST-elevation myocardial infarction (STEMI) (n=150). Cystatin C assessment was evaluated on Elevated LV filling pressure (E/E' > 15) (OR 3.53, 95% CI 1.11-11.26, p=<0.01). Cystatin C assessment independently predicted elevated left ventricular filling pressure (E/E' > 15) at 6 months in patients with a first STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: